New approach to anti-cancer drug development

Pharmacogenomics-A New Approach to Drug Development

Effect of a drug is not always uniform throughout the human population. Drugs working well in one patient population may not work well in another population. Furthermore, some drugs may show adverse reactions with or without intended effects. Some drugs may even fail to exert any effect. Such unpredictable drug effects are due to a generalized approach iadopted for drug development. Today's dru...

A new approach to drug development.

Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.

Cytochrome P450s (CYPs) represent a large class of heme-containing enzymes that catalyze the metabolism of multitudes of substrates both endogenous and exogenous. Until recently, however, CYPs have been largely overlooked in cancer drug development, acknowledged only for their role in phase I metabolism of chemotherapeutics. The first successful strategy targeting CYP enzymes in cancer therapy ...

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy

CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...

Anti-cancer drug discovery and development

Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family anti-apoptotic proteins, as well as selective SMIs to differentially target the two arms. O...